Ruxolitinib Phosphate

  • # LGM Pharma is a Ruxolitinib Phosphate CAS# 1092939-17-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ruxolitinib Phosphate
  • CAS #: 1092939-17-7
  • Mode of Action:

    Ruxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.

  • Pharmacodynamics:

    The mean half-maximal inhibitory concentration (IC50) for JAK 1 and JAK 2 are 2.8 nmol/L and 3.3 nmol/L respectively. After administration of ruxolitinib, a decrease in levels of phosphorylated STAT (marker for JAK activity) in a dose-dependent manner can be observed. Pharmacodynamic resistance has not been observed.

  • Metabolism:

    Ruxolitinib is metabolized by CYP3A4. Less potent active metabolites forms as a result.

  • Toxicity:

    Thrombocytopenia was the dose-limiting toxicity.

  • IUPAC: 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2, 3-d)pyrimidin-4-yl)-, (betaR)-, phosphate (1:1)
  • ATC: L01XE18
  • DrugBank: DB08877
  • Formula: C17-H18-N6.H3-O4-P
  • Molecular Mass: 404.3649
  • Synonyms: 3R)-3-Cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile phosphate (1:1), INCB018424 salt, Jakafi, Jakavi, Ruxolitinib phosphate, UNII-436LRU32H5
  • SMILES: C(#N)C[C@H]([C@@H]1CCCC1)n1ncc(c1)c1ncnc2c1cc[nH]2.P(=O)(O)(O)O
  • AHFS Code: 10:00
  • InChl: 1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
  • General Reference:


    1. Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. Pubmed
    2. Lexi-Comp, Inc. (Lexi-DrugsTM ). Lexi-Comp, Inc.; July, 2013.
    3. Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. Pubmed


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service